Research, programs and tools worth knowing about | Behavioral Healthcare Executive Skip to content Skip to navigation

Research, programs and tools worth knowing about

November 25, 2014
by Julia Brown
| Reprints

Stay informed on what's happening in the industry with these useful updates.


XenoPort, Inc. and the National Institute on Alcohol Abuse and Alcoholism will conduct a clinical trial of HORIZANT (gabapentin enacarbil) extended-release tablets as a potential treatment for alcohol use disorder. The study is expected to have a treatment period of six months and to enroll approximately 350 patients beginning in the first half of 2015.

The Brain & Behavior Research Foundation announced $12.7 million in grants for 200 young scientists. Recipients in neurobiological research will study psychiatric disorders, including anxiety, depression, schizophrenia, autism, bipolar disorder, attention-deficit hyperactive disorder, post-traumatic stress disorder and obsessive compulsive disorder.

A four-year, $16 million grant from the National Institute of Mental Health—shared by the University of Southern California, the University of Michigan and the Broad Institute Inc.—will help fund “Whole Genome Sequencing of Schizophrenia and Bipolar Disorder in the Genomic Psychiatry Cohort” to create a genetic resource for the two disorders.


FDA has approved a new formulation of Abilify Maintena (aripiprazole) for extended-release injectable suspension as a pre-filled dual-chamber syringe. The drug is an atypical antipsychotic indicated for the treatment of schizophrenia.



Rogers Memorial Hospital recently announced that it is adding dual diagnosis addiction treatment services at its Brown Deer, Kenosha, Madison and Oconomowoc locations in Wisconsin.